XML 39 R32.htm IDEA: XBRL DOCUMENT v3.24.3
Collaboration Agreement - Additional Information (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Dec. 31, 2023
Jan. 31, 2023
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 28, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Contract liability revenue recognized     $ 26,030,000 $ 14,957,000 $ 92,670,000 $ 47,171,000  
Contract with customer, performance obligation satisfied in previous period     0   0    
Unrecognized revenue     63,600,000   63,600,000    
Anito-cel              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Clinical milestone achieved     68,300,000   68,300,000    
Anito-cel Next Gen Non-autologous | Maximum              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Potential payments of commercial milestone     507,500,000   507,500,000    
Potential payments of clinical milestone     598,300,000   598,300,000    
Potential payments of regulatory milestone     $ 935,000,000   $ 935,000,000    
Kite Collaboration Agreement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Non-refundable upfront payment received   $ 225,000,000          
Increase in deemed premium on shares sold             $ 15,600,000
Kite Collaboration Agreement and Amendment | United States              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Percentage of out-of-pocket development costs for co-promote products     40.00%   40.00%    
Kite Collaboration Agreement and Amendment | Kite Pharma, Inc. | Outside United States              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Percentage of out-of-pocket development costs for co-promote products     60.00%   60.00%    
Amended Kite Collaboration Agreement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Non-refundable upfront payment received $ 85,000,000            
Gilead Common Stock Purchase Agreement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Shares purchased     3,478,261   3,478,261    
Shares issued, price per share     $ 28.75   $ 28.75    
Reduction of deemed discount on shares sold   15,300,000          
Gilead Common Stock Purchase Agreement | Gilead              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Proceeds from issuance of private placement   $ 100,000,000          
Second Gilead Common Stock Purchase Agreement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Shares purchased 3,242,542   3,242,542   3,242,542    
Shares issued, price per share $ 61.68   $ 61.68   $ 61.68    
Increase in deemed premium on shares sold $ 15,600,000            
Second Gilead Common Stock Purchase Agreement | Gilead              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Proceeds from issuance of private placement $ 200,000,000